Jefferies Global Healthcare Conference

20 November 2014

Disclaimer

The information contained in this document and made verbally to you (together the "Presentation") is confidential and is being supplied, in the United Kingdom only to persons with professional experience in matters relating to investments and/or to high net worth companies as described in Article 19(5) and 49(2) respectively of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI. 2001/No. 1335) (as amended) made pursuant to section 21(5) of the Financial Services and Markets Act 2000 and, if permitted by applicable law, is being supplied outside the United Kingdom to professionals or institutions whose ordinary business involves them in investment activities. The information contained in this document is not intended to be viewed by, or distributed or passed on (directly or indirectly) to, any other class of persons. Recipients of this Presentation should not base any behaviour in relation to the contents of this Presentation, which would amount to market abuse as defined in Section 118 of the Financial Services and Markets Act 2000) until the contents are made generally available to the public.

Accordingly, information contained in the Presentation is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published in whole or in part, for any purpose. In particular, the distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction. In particular, this document is not for distribution in the United States, Australia, Canada or Japan.

This Presentation includes certain statements, estimates and projections with respect to the anticipated future performance of Vectura Group plc, its products and the markets in which it operates. Such statements, estimates and projections reflect the various assumptions made by Vectura Group plc, which assumptions may or may not prove to be correct.

No representation or warranty, express or implied, is given as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation and no liability is accepted for any such information or opinions by Vectura Group plc (the "Company" and, together with its subsidiary undertakings, the "Group") or any of its respective directors, members, officers, employees, agents or advisers. Notwithstanding this, nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently.

This document and the information contained in it does not constitute a prospectus and does not form any part of an offer of, or invitation to purchase or apply for or enter into any contract or make any other commitment whatsoever in relation to, securities. In particular, details included in this Presentation are subject to updating, revision, further verification and amendment. This Presentation does not constitute a recommendation regarding the securities of the Company.

Financial highlights

Revenue growth

Driven by 45% increase in royalties

+ 14%

£19.4m

(H1 2013/14 £17.0m)

EBITDA[1] progression

+ 30%

£3.0m

(H1 2013/14 £2.3m)

Balance sheet strength

Cash and cash equivalents

+ £2.9m

£84.6m

(At 31 March 2014 £81.7m)







Growing royalty revenues from newly-marketed products will support EBITDA[1] progression

[1] Earnings before investment income, finance gains, tax, depreciation, amortisation, share-based compensation and adjusted for non-recurring expenditure

Revenue breakdown

£m	H1 2014/15	H1 2013/14	FY 2013/14
Royalties	10.0	6.9	16.3
Product licensing	3.3	7.8	13.3
Technology licensing	2.2	2.1	4.3
Development services	2.2	0.1	1.7
Device sales	1.7	0.1	0.9
Total revenue	19.4	17.0	36.5

Sustained increase in royalty revenues

+ 45%

(H1 2013/14 £6.9m)

Product licensing revenues include

£2.4m

initial milestone for VR506

R&D investment breakdown

By programme

Key	Programme	Description	H1 2014 £m
	VR315 US	Asthma (US)	3.5
	VR942	Inflammatory airways disease	3.2
	VR876	Pulmonary hypertension	1.4
	VR475	Severe adult asthma	0.9
	Other programmes		1.9
	Investment in technologies		2.3
	Total investment		13.2

R&D investment weighted towards the second half of FY2014/15



Guidance for full-year expenditure in the range of £40m-£45m is maintained

Operational highlights

- Generics pipeline continues to make good progress
  - Two milestones on VR315 US
    - $3m[1] total
  - US licence agreement for VR506 signed
    - Upfront payment of $4m
- Continued roll-out of Novartis partnered assets
- Branded assets continue to grow year-on-year
  - Roll-out of AirFluSal® Forspiro® continues



Source: Total Net Sales booked by Novartis

[1] $1.5m post period

Progression of our business

Accelerating value delivery

- On a journey to build an innovative specialty pharmaceutical business
  - Will continue to carefully assess M&A opportunities
    - Focus is on accretive, revenue-enhancing deals
- Focus on accelerating value in existing pipeline
  - Disciplined prioritised investment in R&D and business development
  - General shift in development focus away from early-stage deals
    - Potential for value realisation must fall within strategic period
- Expert in airways diseases
  - Technology platform and pipeline improved by M&A and selective investment
  - Attracting considerable interest in business development opportunities

Financial perspectives on our business

Poised to generate significant cash flow per share

- Materially advanced our partnered programmes over the past two years
  - High-quality recurring revenues from a growing number of sources
    - Baxter, Novartis, Sandoz, GSK
  - High gross margins associated with royalties
  - Aim to garner increased economics when our technology can be leveraged
- Robust balance sheet maintained through this period
  - Future R&D spend will be prioritised
    - Current FY guidance of £40m-£45m unchanged
  - Maintain estimated range of £40m-£52m over coming years
    - Increased number of revenue-generating opportunities in the near-term
    - Setting transparent medium-term parameters to re-enforce financial discipline
- Significant tax benefits from the patent box has positive impact on valuation

Outlook for revenues

Royalty streams form basis of sustainable growth

Growth drivers

- Products in the growth phase of their launch curve
- Approvals in new geographies
- New product launches

Estimated total value of drug classes in 2018[1] >$22bn



Vectura will benefit from partnered products competing for a share of these major respiratory drug classes globally

[1] Source: Bloomberg analyst consensus estimates

Business development accelerating

Significant increase in active leads post Activaero acquisition



Portfolio overview

Reassessing the value proposition

Delivering on the pipeline expectations

Linking clinical progress with financial objectives

- Nine pipeline assets expected to launch over period to 2021
  - Estimated target market sizes total >$25bn[1]
    - Vectura will compete for share within market segments
- Over $200m in potential milestones from existing deals
    - Approx. $40m related to sales milestones and $160m to development milestones
- Potential revenue CAGR >25% through 2014-2021
  - Operational leverage achieved by maintaining expenses within tight limits
    - R&D to be kept within stated range
  - Portfolio prioritisation assists in controlling R&D annual spend

[1] Source Decision Resources 2014 Pharmacor series. Note NVA237 & QVA149 potential includes global sales

Portfolio review

Aligning resources with the strategy

- Near-term priorities to becoming a specialty pharmaceutical company
  - Accelerate the overall value of our existing pipeline
  - Demonstrate value realisation in our pipeline
- Development focus will change over time
  - Current partnered programmes unaffected, partner obligations are contractual and must be supported
  - Seek to focus on value realisation from later-stage products
  - Development support (both device & technology) of deal opportunities is paramount
- How does that impact our existing pipeline?

Pipeline

Partnered
Wholly owned
Generic

VR588
Severe Inflammatory Airways Disease (Global)

VR611
Airways Inflammation & Chronic Cough (Global)

VR942 (UCB)
Inflammatory Airways disease (Co-development global)

VR475
Severe Adult Asthma (US)

VR465 (Ablynx)
RSV Infection (Global)

VR647
Paediatric Asthma (Global)

VR179 (Grifols)
Cystic Fibrosis (Global)

VR736 (Ventaleon)
Severe Influenza (Global)

NVA237 (Novartis)
COPD (US)

QVA149 (Novartis)
COPD (US)

VR475
Severe Adult Asthma (EU)

VR876 (partnered, undisclosed)
Pulmonary Hypertension (Global)

VR315 (undisclosed partner)
Asthma (US)

VR506 (undisclosed partner)
Asthma (US)

VR632 (Sandoz)
Asthma (EU)

Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Full development | Filed

Assets impacted by portfolio review

- VR475 EU (FAVOLIR®)
  - Phase III study anticipated to start in H1 2015 with filing anticipated in Q2 2018
  - Expanded commercial opportunity
- VR647 (SCIPE) and VR475 US
  - Analysis suggests a larger opportunity by combining both projects
  - Development plan will be discussed with FDA
  - Evaluating incoming licensing requests to expedite value return
- VR588 (Pan-JAK kinase inhibitor)
  - Focus on the asthma indication; multiple additional indications possible
  - Minimise investment and focus on activities that support licensing
- VR611 (TRPV1 receptor modulator)
  - Minimise investment and focus on activities that support licensing

VR475: Clinical Phase III trial design

Inhaled, add-on therapy to improve asthma control in patients with severe, uncontrolled, persistent asthma who continue to experience exacerbations

Phase III double-blind, placebo-controlled study of patients with severe, uncontrolled, persistent asthma	
Parameters	
Patients	Approximately 500 GINA step 4 and 5 patients with a history of exacerbations
Treatments	Two doses VR475 (1mg & 0.5mg); placebo and conventionally nebulised budesonide
Endpoints	Exacerbations; OCS-sparing, asthma control (FEV_1) and QoL
Duration	52-week treatment period, 4-week follow-up
Sites	c.100 sites across EU

vectura

Outlook

Success factors

Foundations for the next stage of our journey

- Broad and deep pipeline
  - Risk/reward balanced by robust portfolio of partnered programmes
- Depth and breadth of technology/device platform
- Partner of choice
  - Leader in cutting-edge technologies that support products
- Portfolio has been augmented through successful licensing deals and M&A
  - Novartis, Sandoz, UCB, GSK
  - M&A has brought assets and new partners
    - Baxter, Kinnovata, Grifols, Ablynx

Evolving business model

Near term focus on deal flow

- We aim to operate a hybrid model focused on:
  - Driving R&D to earliest inflection point for value realisation
    - Partnering, co-development and potential self-commercialisation
  - Continuing to evaluate the landscape for attractive opportunities
- Royalty model has been demonstrably successful
  - High-margin, high-growth, recurring revenue
  - Patent box tax incentives
- Continued disciplined cash control augmented by portfolio prioritisation
  - Will enable R&D costs to be contained within limits over a period of time
  - Broad portfolio diversity enhances chances of success
- Transitioning to becoming a specialty pharmaceutical company